Ischemia Reperfusion Injury Therapeutics Market Report and Forecast 2025-2034

Published Jul 29, 2025

Length 350 Pages

SKU # EMAR20319992

Description

The ischemia reperfusion injury therapeutics market size was valued at USD 1.67 Billion in 2024, driven by the prevalence of chronic diseases in a geriatric population across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2025-2034, with the values likely to reach USD 2.62 Billion by 2034.

Ischemia Reperfusion Injury Therapeutics: Introduction

Ischemia reperfusion injury, also known as reperfusion injury or reoxygenation injury, occurs when blood supply returns to an ischemic area, leading to sudden tissue death. Instead of facilitating normal function in the cell, the restoration of oxygen and nutrients leads to inflammation and oxidative damage.

Ischemia Reperfusion Injury Therapeutics Market Analysis

Ischemia-reperfusion injury is a major cause of multi-organ malfunction post a severe trauma with heavy bleeding. IRI occurrence may also lead to severe cardiac, pulmonary, spinal cord renal, hepatic and limb problems. Hence, the ischemia-reperfusion injury therapeutics market demand has increased.

Metformin, a plant-based anti-hyperglycemic drug having multiple mechanisms of action, has been a common ischemia reperfusion injury drug. It modulates ROS (reactive oxygen species) levels and oxidative damage during reperfusion, preventing organ malfunction. Focusing on kidney transplantation, Treprostinil (Remodulin) is another antihypertensive agent which is formulated as an injectable solution, also being considered for the treatment of ischemia-reperfusion injury.

With the emergence of nanotechnology in the medical field and a better understanding of cell interactions, scientists have diverted towards applying nanoparticle-mediated medicine. It can be considered an effective therapy owing to its enhanced drug accumulation, reduced systemic toxicity and improved pharmacokinetics. Numerous biomaterials like microneedles, liposomes, cardiac patches, and hydrogels are being explored as a potential tool for treatment. Given the substantial research efforts dedicated to this area, the ischemia-reperfusion injury therapeutics market value is estimated to rise significantly during the forecast period.

Ischemia Reperfusion Injury Therapeutics Market Segmentation
"Ischemia Reperfusion Injury Therapeutics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment Type

Drug Therapy

Antioxidants

Anti-Inflammatory Agents

Vasodilators

Immunomodulators

Others

Medicated Gases
Others

Market Breakup by Indications

Heart Injury
Kidney Injury
Intestine Injury
Other Injury

Market Breakup by Route of Administration

Oral
Parenteral
Topical
Inhalation

Market Breakup by End User

Hospitals and Clinics
Ambulatory Surgical Centres
Research Institutes
Others

Market Breakup by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Market Breakup by Region– 7MM

United States
EU-4 and the United Kingdom
Japan

Ischemia Reperfusion Injury Therapeutics Market Overview

Cardiovascular diseases continue to be some of the most chronic diseases worldwide, still affecting the lives of millions. Myocardial ischemia-reperfusion accounts for approximately 1.72% of deaths and disabilities in the global population. With the prevalence of cardiovascular, neurological, and kidney-related diseases, North America has held a significant part of the ischemia-reperfusion injury therapeutics market share in the historic period. A technologically advanced infrastructure, rising research and developments in medical care facilities and capital investments are key factors accountable for the market size.

The Asia Pacific region is expected to witness exponential growth in the coming years owing to the presence of a geriatric population that may lead to an increased incidence of chronic diseases like myocardial infarction. Moreover, the government initiatives to build technology-supportive infrastructure, an influx of foreign funds due to the easy availability of resources and the emergence of healthcare startups, can bring some substantial innovations in the ischemia reperfusion injury therapeutics market.

Ischemia Reperfusion Injury Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Pfizer Inc.
AstraZeneca PLC
Novartis International AG
Merck & Co., Inc.
Johnson & Johnson
Bayer AG
Sanofi SA
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
AbbVie Inc.
Amgen Inc.
Gilead Sciences, Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Biogen Inc.
Regeneron Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Grifols, S.A.

*Please Note:* The report will take 5 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Ischemia Reperfusion Injury Overview: 3.1 Guidelines and Stages; 3.2 Pathophysiology; 3.3 Screening and Diagnosis; 3.4 Treatment Pathway
4 Patient Profile: 4.1 Patient Profile Overview; 4.2 Patient Psychology and Emotional Impact Factors; 4.3 Risk Assessment and Treatment Success Rate
5 Ischemia Reperfusion Injury Epidemiology Analysis- 7MM: 5.1 Epidemiology Overview (2018-2034); 5.2 United States Ischemia Reperfusion Injury Epidemiology (2018-2034); 5.3 EU-4 and United Kingdom Ischemia Reperfusion Injury Epidemiology (2018-2034); 5.4 Japan Ischemia Reperfusion Injury Epidemiology (2018-2034)
6 Ischemia Reperfusion Injury Therapeutics Market Overview: 6.1 Ischemia Reperfusion Injury Therapeutics Market Historical Value (2018-2024); 6.2 Ischemia Reperfusion Injury Therapeutics Market Forecast Value (2025-2034)
7 Ischemia Reperfusion Injury Therapeutics Market Landscape: 7.1 Ischemia Reperfusion Injury Therapeutics: Developers Landscape; 7.1.1 Analysis by Year of Establishment; 7.1.2 Analysis by Company Size; 7.1.3 Analysis by Region; 7.2 Ischemia Reperfusion Injury Therapeutics: Product Landscape; 7.2.1 Analysis by Treatment Type; 7.2.2 Analysis by Indications; 7.2.3 Analysis by Route of Administration
8 Ischemia Reperfusion Injury Therapeutics Challenges and Unmet Needs: 8.1 Treatment Pathway Challenges; 8.2 Compliance and Drop-Out Analysis; 8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ischemia Reperfusion Injury Therapeutics Market Dynamics: 10.1 Market Drivers and Constraints; 10.2 SWOT Analysis; 10.3 Porter’s Five Forces Model; 10.4 Key Demand Indicators; 10.5 Key Price Indicators; 10.6 Industry Events, Initiatives, and Trends; 10.7 Value Chain Analysis
11 Ischemia Reperfusion Injury Therapeutics Market Segmentation: 11.1 Ischemia Reperfusion Injury Therapeutics Market by Treatment Type; 11.1.1 Market Overview; 11.1.2 Drug Therapy; 11.1.2.1 Antioxidants; 11.1.2.2 Anti-Inflammatory Agents; 11.1.2.3 Vasodilators; 11.1.2.4 Immunomodulators; 11.1.2.5 Others; 11.1.3 Medicated Gases; 11.1.4 Others; 11.2 Ischemia Reperfusion Injury Therapeutics Market by Indications; 11.2.1 Market Overview; 11.2.2 Heart Injury; 11.2.3 Kidney Injury; 11.2.4 Intestine Injury; 11.2.5 Other Injury; 11.3 Ischemia Reperfusion Injury Therapeutics Market by Route of Administration; 11.3.1 Market Overview; 11.3.2 Oral; 11.3.3 Parenteral; 11.3.4 Topical; 11.3.5 Inhalation; 11.4 Ischemia Reperfusion Injury Therapeutics Market by End User; 11.4.1 Market Overview; 11.4.2 Hospitals and Clinics; 11.4.3 Ambulatory Surgical Centres; 11.4.4 Research Institutes; 11.4.5 Others; 11.5 Ischemia Reperfusion Injury Therapeutics Market by Distribution Channel; 11.5.1 Market Overview; 11.5.2 Hospital Pharmacies; 11.5.3 Retail Pharmacies; 11.5.4 Online Pharmacies; 11.5.5 Others; 11.6 Ischemia Reperfusion Injury Therapeutics Market by Region– 7MM; 11.6.1 Market Overview; 11.6.2 United States; 11.6.3 EU-4 and the United Kingdom; 11.6.4 Japan
12 United States Ischemia Reperfusion Injury Therapeutics Market: 12.1 U.S. Ischemia Reperfusion Injury Therapeutics Market Historical Size (2018-2024); 12.2 U.S. Ischemia Reperfusion Injury Therapeutics Market Forecast Size (2025-2034); 12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Ischemia Reperfusion Injury Therapeutics Market: 13.1 EU-5 and the United Kingdom Ischemia Reperfusion Injury Therapeutics Market Historical Size (2018-2024); 13.2 EU-5 and the United Kingdom Ischemia Reperfusion Injury Therapeutics Market Forecast Size (2025-2034); 13.3 Market Size by Therapeutic Class
14 Japan Ischemia Reperfusion Injury Therapeutics Market: 14.1 Japan Ischemia Reperfusion Injury Therapeutics Market Historical Size (2018-2024); 14.2 Japan Ischemia Reperfusion Injury Therapeutics Market Forecast Size (2025-2034); 14.3 Market Size by Therapeutic Class
15 Regulatory Framework: 15.1 Regulatory Overview; 15.1.1 US FDA; 15.1.2 EU EMA; 15.1.3 JAPAN PMDA
16 Patent Analysis: 16.1 Analysis by Type of Patent; 16.2 Analysis by Publication year; 16.3 Analysis by Issuing Authority; 16.4 Analysis by Patent Age; 16.5 Analysis by CPC Analysis; 16.6 Analysis by Patent Valuation; 16.7 Analysis by Key Players
17 Grants Analysis: 17.1 Analysis by year; 17.2 Analysis by Amount Awarded; 17.3 Analysis by Issuing Authority; 17.4 Analysis by Grant Application; 17.5 Analysis by Funding Institute; 17.6 Analysis by NIH Departments; 17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis: 18.1 Analysis by Trial Registration Year; 18.2 Analysis by Trial Status; 18.3 Analysis by Trial Phase; 18.4 Analysis by Therapeutic Area; 18.5 Analysis by Geography
19 Funding and Investment Analysis: 19.1 Analysis by Funding Instances; 19.2 Analysis by Type of Funding; 19.3 Analysis by Funding Amount; 19.4 Analysis by Leading Players; 19.5 Analysis by Leading Investors; 19.6 Analysis by Geography
20 Partnership and Collaborations Analysis: 20.1 Analysis by Partnership Instances; 20.2 Analysis by Type of Partnership; 20.3 Analysis by Leading Players; 20.4 Analysis by Geography
21 Supplier Landscape: 21.1 Pfizer Inc.; 21.1.1 Financial Analysis; 21.1.2 Product Portfolio; 21.1.3 Demographic Reach and Achievements; 21.1.4 Mergers and Acquisitions; 21.1.5 Certifications; 21.2 AstraZeneca PLC; 21.2.1 Financial Analysis; 21.2.2 Product Portfolio; 21.2.3 Demographic Reach and Achievements; 21.2.4 Mergers and Acquisitions; 21.2.5 Certifications; 21.3 Novartis International AG; 21.3.1 Financial Analysis; 21.3.2 Product Portfolio; 21.3.3 Demographic Reach and Achievements; 21.3.4 Mergers and Acquisitions; 21.3.5 Certifications; 21.4 Merck & Co., Inc.; 21.4.1 Financial Analysis; 21.4.2 Product Portfolio; 21.4.3 Demographic Reach and Achievements; 21.4.4 Mergers and Acquisitions; 21.4.5 Certifications; 21.5 Johnson & Johnson; 21.5.1 Financial Analysis; 21.5.2 Product Portfolio; 21.5.3 Demographic Reach and Achievements; 21.5.4 Mergers and Acquisitions; 21.5.5 Certifications; 21.6 Bayer AG; 21.6.1 Financial Analysis; 21.6.2 Product Portfolio; 21.6.3 Demographic Reach and Achievements; 21.6.4 Mergers and Acquisitions; 21.6.5 Certifications; 21.7 Sanofi SA; 21.7.1 Financial Analysis; 21.7.2 Product Portfolio; 21.7.3 Demographic Reach and Achievements; 21.7.4 Mergers and Acquisitions; 21.7.5 Certifications; 21.8 GlaxoSmithKline plc; 21.8.1 Financial Analysis; 21.8.2 Product Portfolio; 21.8.3 Demographic Reach and Achievements; 21.8.4 Mergers and Acquisitions; 21.8.5 Certifications; 21.9 Boehringer Ingelheim International GmbH; 21.9.1 Financial Analysis; 21.9.2 Product Portfolio; 21.9.3 Demographic Reach and Achievements; 21.9.4 Mergers and Acquisitions; 21.9.5 Certifications; 21.10 Bristol-Myers Squibb Company; 21.10.1 Financial Analysis; 21.10.2 Product Portfolio; 21.10.3 Demographic Reach and Achievements; 21.10.4 Mergers and Acquisitions; 21.10.5 Certifications; 21.11 AbbVie Inc.; 21.11.1 Financial Analysis; 21.11.2 Product Portfolio; 21.11.3 Demographic Reach and Achievements; 21.11.4 Mergers and Acquisitions; 21.11.5 Certifications; 21.12 Amgen Inc.; 21.12.1 Financial Analysis; 21.12.2 Product Portfolio; 21.12.3 Demographic Reach and Achievements; 21.12.4 Mergers and Acquisitions; 21.12.5 Certifications; 21.13 Gilead Sciences, Inc.; 21.13.1 Financial Analysis; 21.13.2 Product Portfolio; 21.13.3 Demographic Reach and Achievements; 21.13.4 Mergers and Acquisitions; 21.13.5 Certifications; 21.14 F. Hoffmann-La Roche Ltd.; 21.14.1 Financial Analysis; 21.14.2 Product Portfolio; 21.14.3 Demographic Reach and Achievements; 21.14.4 Mergers and Acquisitions; 21.14.5 Certifications; 21.15 Eli Lilly and Company; 21.15.1 Financial Analysis; 21.15.2 Product Portfolio; 21.15.3 Demographic Reach and Achievements; 21.15.4 Mergers and Acquisitions; 21.15.5 Certifications; 21.16 Takeda Pharmaceutical Company Limited; 21.16.1 Financial Analysis; 21.16.2 Product Portfolio; 21.16.3 Demographic Reach and Achievements; 21.16.4 Mergers and Acquisitions; 21.16.5 Certifications; 21.17 Biogen Inc.; 21.17.1 Financial Analysis; 21.17.2 Product Portfolio; 21.17.3 Demographic Reach and Achievements; 21.17.4 Mergers and Acquisitions; 21.17.5 Certifications; 21.18 Regeneron Pharmaceuticals, Inc.; 21.18.1 Financial Analysis; 21.18.2 Product Portfolio; 21.18.3 Demographic Reach and Achievements; 21.18.4 Mergers and Acquisitions; 21.18.5 Certifications; 21.19 Mitsubishi Tanabe Pharma Corporation; 21.19.1 Financial Analysis; 21.19.2 Product Portfolio; 21.19.3 Demographic Reach and Achievements; 21.19.4 Mergers and Acquisitions; 21.19.5 Certifications; 21.20 Grifols, S.A.; 21.20.1 Financial Analysis; 21.20.2 Product Portfolio; 21.20.3 Demographic Reach and Achievements; 21.20.4 Mergers and Acquisitions; 21.20.5 Certifications
22 Ischemia Reperfusion Injury Therapeutics - Distribution Model (Additional Insight): 22.1 Overview; 22.2 Potential Distributors; 22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight): 24.1 Very Small Companies; 24.2 Small Companies; 24.3 Mid-Sized Companies; 24.4 Large Companies; 24.5 Very Large Companies
25 Payment Methods (Additional Insight): 25.1 Government Funded; 25.2 Private Insurance; 25.3 Out-of-Pocket

Pricing

Currency Rates

Single User Email from Publisher $4,949
Global Site License Email from Publisher $6,969

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now